Answers are grounded in this paper and cite their sources.
Explores PDLIM2's role in lung adenocarcinoma, suggesting its potential as a therapeutic target.
Background While PDZ-LIM domain-containing protein (PDLIM2) suppresses lung cancer, its clinical significance and therapeutic potential remain to be fully explored. Methods Next-generation sequencing and immunohistochemistry of programmed death ligand 1 (PD-L1) were performed on lung adenocarcinoma (LUAD) tissues from 15,765 patients. PDLIM2 gene therapy was tested in syngeneic LUAD mouse models using intravenous nano-complexed plasmid DNA, alone or with chemoimmunotherapy. Results PDLIM2 -high tumors were more common in primary/local biopsies versus metastatic samples (73.1% vs 53.0%; p < 0.001). High PDLIM2 expression was linked to lower mutation rates in RB1 , TP53 , SMARCA4, STK11 , and KEAP1 , but increased EGFR mutations (all p < 0.01). PDLIM2 -high tumors also showed increased immune cell infiltration, T cell-inflamed scores, and PD-L1 positivity (all p < 0.008). High PDLIM2 was associated with improved survival (24.1 vs 18.1 months; p < 0.001, HR = 0.84) and remained prognostic in multivariate analysis (HR = 0.88, 95% CI 0.83–0.93), as well as with longer pembrolizumab time, especially with platinum-based therapy ( p = 0.012, HR = 0.867). In two LUAD mouse models, nanoPDLIM2 improved median overall survival versus chemoimmunotherapy alone (10–12.5 vs 8–9 days; N = 8; p = 0.0001, 0.0003). Conclusion PDLIM2 is a promising prognostic biomarker in LUAD linked to immune-receptive tumors. Preclinically, PDLIM2 -based therapy enhances chemoimmunotherapy efficacy, though its predictive role warrants further evaluation.
No takes yet. Share an insight, caveat, or question.
Ashouri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: